Bicycle Therapeutics Stock Forecast, Price & News

-0.01 (-0.03 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume16,989 shs
Average Volume136,394 shs
Market Capitalization$714.88 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Bicycle Therapeutics logo

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.35 out of 5 stars

Medical Sector

810th out of 2,100 stocks

Pharmaceutical Preparations Industry

399th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

Is Bicycle Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bicycle Therapeutics stock.
View analyst ratings for Bicycle Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Bicycle Therapeutics?

Wall Street analysts have given Bicycle Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bicycle Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bicycle Therapeutics' next earnings date?

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Bicycle Therapeutics

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) posted its quarterly earnings results on Thursday, May, 6th. The company reported ($0.73) EPS for the quarter, missing the Zacks' consensus estimate of ($0.68) by $0.05. The business earned $1.81 million during the quarter, compared to analyst estimates of $1.95 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 53.45% and a negative net margin of 504.81%.
View Bicycle Therapeutics' earnings history

How has Bicycle Therapeutics' stock been impacted by COVID-19?

Bicycle Therapeutics' stock was trading at $17.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BCYC shares have increased by 67.7% and is now trading at $29.69.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BCYC?

6 brokerages have issued 1 year target prices for Bicycle Therapeutics' shares. Their forecasts range from $25.00 to $58.00. On average, they expect Bicycle Therapeutics' share price to reach $43.00 in the next year. This suggests a possible upside of 44.8% from the stock's current price.
View analysts' price targets for Bicycle Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bicycle Therapeutics' key executives?

Bicycle Therapeutics' management team includes the following people:
  • Dr. Kevin Lee M.B.A., Ph.D., CEO & Exec. Director (Age 51, Pay $1.01M)
  • Mr. Lee H. Kalowski, Pres & CFO (Age 40, Pay $654.18k)
  • Sir Gregory Paul Winter, Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board (Age 70, Pay $23.95k)
  • Dr. Michael Skynner Ph.D., Ph.d., Chief Operating Officer (Age 51, Pay $626.03k)
  • Dr. Christian Heinis, Scientific Founder
  • Dr. Nicholas Keen, Chief Scientific Officer (Age 52)
  • Mr. Zafar Qadir, Gen. Counsel
  • Dr. Gillian Langford, Head of Clinical and Project Management
  • Ms. Rosamond Deegan, Pres of U.S. and Chief Bus. Officer of U.S. (Age 49)
  • Dr. Phil Jeffrey, Sr. VP of Pre-Clinical Devel.

Who are some of Bicycle Therapeutics' key competitors?

What other stocks do shareholders of Bicycle Therapeutics own?

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (7.05%), Point72 Asset Management L.P. (6.57%), Logos Global Management LP (3.33%), FIL Ltd (2.18%), Verition Fund Management LLC (1.00%) and Victory Capital Management Inc. (0.78%). Company insiders that own Bicycle Therapeutics stock include Kevin Lee, Lee Kalowski, Nicholas Keen, Pierre Legault and Plc Glaxosmithkline.
View institutional ownership trends for Bicycle Therapeutics

Which major investors are selling Bicycle Therapeutics stock?

BCYC stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Bank of New York Mellon Corp, and US Bancorp DE. Company insiders that have sold Bicycle Therapeutics company stock in the last year include Kevin Lee, Lee Kalowski, Nicholas Keen, Pierre Legault, and Plc Glaxosmithkline.
View insider buying and selling activity for Bicycle Therapeutics
or view top insider-selling stocks.

Which major investors are buying Bicycle Therapeutics stock?

BCYC stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Logos Global Management LP, FIL Ltd, Verition Fund Management LLC, Ghost Tree Capital LLC, Point72 Asset Management L.P., Parkman Healthcare Partners LLC, and Acadian Asset Management LLC.
View insider buying and selling activity for Bicycle Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $29.69.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics has a market capitalization of $714.88 million and generates $10.39 million in revenue each year. The company earns $-51,010,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

Bicycle Therapeutics employs 87 workers across the globe.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is

Where are Bicycle Therapeutics' headquarters?

Bicycle Therapeutics is headquartered at B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 441223261503.

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.